id,sequence,label,elisa_flags,source
abituzumab,YTS,0.0,0,jain2017_pnas
abrilumab,GAS,0.0,0,jain2017_pnas
adalimumab,AAS,0.0,0,jain2017_pnas
alemtuzumab,NTN,0.0,0,jain2017_pnas
alirocumab,WAS,0.0,0,jain2017_pnas
anifrolumab,GAS,0.0,0,jain2017_pnas
atezolizumab,SAS,0.0,0,jain2017_pnas
bapineuzumab,LVS,0.0,0,jain2017_pnas
basiliximab,DTS,0.0,0,jain2017_pnas
bavituximab,ATS,0.0,0,jain2017_pnas
belimumab,GKN,1.0,6,jain2017_pnas
benralizumab,HTS,0.0,0,jain2017_pnas
bevacizumab,FTS,0.0,0,jain2017_pnas
bimagrumab,GVS,0.0,0,jain2017_pnas
blosozumab,WAS,1.0,6,jain2017_pnas
bococizumab,SAS,1.0,6,jain2017_pnas
brentuximab,AAS,,3,jain2017_pnas
briakinumab,YND,1.0,4,jain2017_pnas
brodalumab,DAS,,1,jain2017_pnas
canakinumab,YAS,0.0,0,jain2017_pnas
carlumab,DAS,1.0,4,jain2017_pnas
certolizumab,SAS,0.0,0,jain2017_pnas
cetuximab,YAS,0.0,0,jain2017_pnas
cixutumumab,GEN,1.0,6,jain2017_pnas
clazakizumab,RAS,0.0,0,jain2017_pnas
codrituzumab,KVS,1.0,6,jain2017_pnas
crenezumab,KVS,0.0,0,jain2017_pnas
dacetuzumab,TVS,0.0,0,jain2017_pnas
daclizumab,TTS,,1,jain2017_pnas
dalotuzumab,KVS,1.0,5,jain2017_pnas
daratumumab,DAS,0.0,0,jain2017_pnas
denosumab,GAS,1.0,5,jain2017_pnas
dinutuximab,KVS,0.0,0,jain2017_pnas
drozitumab,GAN,0.0,0,jain2017_pnas
duligotuzumab,SAS,1.0,6,jain2017_pnas
dupilumab,LGS,1.0,5,jain2017_pnas
eculizumab,GAT,0.0,0,jain2017_pnas
efalizumab,SGS,0.0,0,jain2017_pnas
eldelumab,GAS,0.0,0,jain2017_pnas
elotuzumab,WAS,0.0,0,jain2017_pnas
emibetuzumab,STS,1.0,6,jain2017_pnas
enokizumab,GTS,0.0,0,jain2017_pnas
epratuzumab,WAS,,1,jain2017_pnas
etrolizumab,YAS,,2,jain2017_pnas
evolocumab,EVS,,2,jain2017_pnas
farletuzumab,GTS,0.0,0,jain2017_pnas
fasinumab,AAF,0.0,0,jain2017_pnas
fezakinumab,GDS,0.0,0,jain2017_pnas
ficlatuzumab,GAS,0.0,0,jain2017_pnas
figitumumab,AAS,,3,jain2017_pnas
fletikumab,DAS,0.0,0,jain2017_pnas
foralumab,DAS,,2,jain2017_pnas
fresolimumab,GAS,0.0,0,jain2017_pnas
fulranumab,DAS,,1,jain2017_pnas
galiximab,DIN,0.0,0,jain2017_pnas
ganitumab,LGS,0.0,0,jain2017_pnas
gantenerumab,GAS,1.0,6,jain2017_pnas
gemtuzumab,AAS,0.0,0,jain2017_pnas
gevokizumab,YTS,0.0,0,jain2017_pnas
girentuximab,SAS,0.0,0,jain2017_pnas
glembatumumab,GAS,0.0,0,jain2017_pnas
golimumab,DAS,,1,jain2017_pnas
guselkumab,GNS,,1,jain2017_pnas
ibalizumab,WAS,0.0,0,jain2017_pnas
imgatuzumab,NTN,1.0,5,jain2017_pnas
infliximab,YAS,0.0,0,jain2017_pnas
inotuzumab,GIS,,3,jain2017_pnas
ipilimumab,GAF,0.0,0,jain2017_pnas
ixekizumab,KVS,1.0,6,jain2017_pnas
lampalizumab,GGN,0.0,0,jain2017_pnas
lebrikizumab,LAS,0.0,0,jain2017_pnas
lenzilumab,STS,1.0,6,jain2017_pnas
lintuzumab,AAS,0.0,0,jain2017_pnas
lirilumab,DAS,0.0,0,jain2017_pnas
lumiliximab,VAS,0.0,0,jain2017_pnas
matuzumab,DTS,0.0,0,jain2017_pnas
mavrilimumab,HNN,0.0,0,jain2017_pnas
mepolizumab,GAS,0.0,0,jain2017_pnas
mogamulizumab,KVS,0.0,0,jain2017_pnas
motavizumab,DTS,,1,jain2017_pnas
muromonab,DTS,0.0,0,jain2017_pnas
natalizumab,YTS,0.0,0,jain2017_pnas
necitumumab,DAS,0.0,0,jain2017_pnas
nimotuzumab,KVS,0.0,0,jain2017_pnas
nivolumab,DAS,0.0,0,jain2017_pnas
obinutuzumab,QMS,0.0,0,jain2017_pnas
ocrelizumab,APS,0.0,0,jain2017_pnas
ofatumumab,DAS,0.0,0,jain2017_pnas
olaratumab,DAS,0.0,0,jain2017_pnas
olokizumab,NAN,0.0,0,jain2017_pnas
omalizumab,AAS,0.0,0,jain2017_pnas
onartuzumab,WAS,0.0,0,jain2017_pnas
otelixizumab,DDD,0.0,0,jain2017_pnas
otlertuzumab,FAK,0.0,0,jain2017_pnas
ozanezumab,LMS,,3,jain2017_pnas
palivizumab,DTS,0.0,0,jain2017_pnas
panitumumab,DAS,0.0,0,jain2017_pnas
panobacumab,KVS,0.0,0,jain2017_pnas
parsatuzumab,RVS,1.0,6,jain2017_pnas
patritumab,WAS,1.0,4,jain2017_pnas
pembrolizumab,LAS,0.0,0,jain2017_pnas
pertuzumab,SAS,0.0,0,jain2017_pnas
pinatuzumab,KVS,0.0,0,jain2017_pnas
polatuzumab,AAS,0.0,0,jain2017_pnas
ponezumab,QIS,1.0,4,jain2017_pnas
radretumab,YAS,0.0,0,jain2017_pnas
ramucirumab,DAS,0.0,0,jain2017_pnas
ranibizumab,FTS,,1,jain2017_pnas
reslizumab,GAN,0.0,0,jain2017_pnas
rilotumumab,GAS,0.0,0,jain2017_pnas
rituximab,ATS,0.0,0,jain2017_pnas
robatumumab,YAS,1.0,4,jain2017_pnas
romosozumab,YTS,0.0,0,jain2017_pnas
sarilumab,GAS,0.0,0,jain2017_pnas
secukinumab,GAS,0.0,0,jain2017_pnas
seribantumab,EVS,0.0,0,jain2017_pnas
sifalimumab,GAS,,3,jain2017_pnas
siltuximab,DTS,0.0,0,jain2017_pnas
simtuzumab,RMS,1.0,6,jain2017_pnas
sirukumab,DMS,1.0,5,jain2017_pnas
tabalumab,DAS,0.0,0,jain2017_pnas
tanezumab,YTS,,1,jain2017_pnas
teplizumab,DTS,,2,jain2017_pnas
tigatuzumab,WAS,0.0,0,jain2017_pnas
tildrakizumab,NAK,0.0,0,jain2017_pnas
tocilizumab,YTS,0.0,0,jain2017_pnas
tovetumab,AAS,0.0,0,jain2017_pnas
tralokinumab,DDG,0.0,0,jain2017_pnas
trastuzumab,SAS,0.0,0,jain2017_pnas
tremelimumab,AAS,0.0,0,jain2017_pnas
urelumab,DAS,0.0,0,jain2017_pnas
ustekinumab,AAS,,3,jain2017_pnas
vedolizumab,GIS,0.0,0,jain2017_pnas
veltuzumab,ATS,0.0,0,jain2017_pnas
visilizumab,DTS,,3,jain2017_pnas
zalutumumab,DAS,,1,jain2017_pnas
zanolimumab,AAS,0.0,0,jain2017_pnas
